Island Pharmaceuticals Ltd (AU:ILA)
ASX:ILA
Want to see AU:ILA full AI Analyst Report?
Top Page
Island Pharmaceuticals Ltd
(Sydney:ILA)
Select Model
Select Model
Rating:43Neutral
Price Target:
AU$0.36
▼(-18.86% Downside)
Action:ReiteratedDate:03/05/26
The score is held down primarily by weak operating performance and continued cash burn, despite a clean, low-debt balance sheet. Technical indicators show subdued momentum, and valuation provides limited support given negative earnings and no dividend data.
Positive Factors
Low Debt & Strong Equity
A zero-debt balance sheet with materially higher equity enhances solvency and reduces refinancing risk, giving management flexibility to fund clinical programs and partnerships. Over 2–6 months this structural strength lowers bankruptcy risk and supports execution of development milestones.
Negative Factors
Sharp Revenue Decline
A ~70% year-over-year revenue collapse materially weakens internal funding capacity and signals volatility in commercial or licensing income. Persistently low revenues constrain reinvestment in R&D and increase reliance on external financing, raising execution risk over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Debt & Strong Equity
A zero-debt balance sheet with materially higher equity enhances solvency and reduces refinancing risk, giving management flexibility to fund clinical programs and partnerships. Over 2–6 months this structural strength lowers bankruptcy risk and supports execution of development milestones.
Read all positive factors
Island Pharmaceuticals Ltd (ILA) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$109.49M
Dividend YieldN/A
Average Volume (3M)781.24K
Price to Earnings (P/E)―
Beta (1Y)-0.88
Revenue GrowthN/A
EPS Growth-9.57%
CountryAU
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.02
Shares Outstanding295,916,700
10 Day Avg. Volume388,484
30 Day Avg. Volume781,243
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)3.39
Price to Sales (P/S)204.10
P/FCF Ratio-8.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Island Pharmaceuticals Ltd Business Overview & Revenue Model
Company Description
Island Pharmaceuticals Limited, a drug research and repurposing company, focuses on the development of preventative or therapeutic drugs for viral infections. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengu...
How the Company Makes Money
null...
Island Pharmaceuticals Ltd Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
66
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 22.07K | 118.91K | 1.25M | 11.06K | 0.00 | 0.00 |
| Gross Profit | -729.59K | -1.29M | -1.01M | 11.06K | 0.00 | 0.00 |
| EBITDA | -4.90M | 0.00 | -2.82M | -2.82M | -2.61M | -2.13M |
| Net Income | -7.20M | -3.92M | -2.86M | -2.83M | -2.61M | -2.13M |
Balance Sheet | ||||||
| Total Assets | 8.02M | 7.49M | 2.56M | 2.05M | 4.90M | 6.64M |
| Cash, Cash Equivalents and Short-Term Investments | 6.87M | 7.25M | 1.66M | 2.00M | 4.79M | 6.46M |
| Total Debt | 0.00 | 0.00 | 421.97K | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 860.15K | 336.43K | 1.05M | 263.85K | 580.73K | 236.83K |
| Stockholders Equity | 7.16M | 7.16M | 1.52M | 1.79M | 4.32M | 6.40M |
Cash Flow | ||||||
| Free Cash Flow | -3.67M | -2.77M | -3.16M | -2.71M | -1.88M | -938.24K |
| Operating Cash Flow | -3.67M | -2.77M | -3.16M | -2.71M | -1.88M | -938.24K |
| Investing Cash Flow | -841.70K | 0.00 | 0.00 | 0.00 | 0.00 | 77.37K |
| Financing Cash Flow | 7.41M | 8.36M | 2.79M | -171.36K | 0.00 | 7.30M |
Island Pharmaceuticals Ltd Technical Analysis
Negative
0.44
Price Trends
0.39
Negative
0.43
Negative
0.36
Negative
Market Momentum
-0.01
Positive
42.68
Neutral
29.17
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ILA, the sentiment is Negative. The current price of 0.44 is above the 20-day moving average (MA) of 0.37, above the 50-day MA of 0.39, and above the 200-day MA of 0.36, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 42.68 is Neutral, neither overbought nor oversold. The STOCH value of 29.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:ILA.
Island Pharmaceuticals Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | AU$76.58M | -7.57 | -179.37% | ― | ― | 24.59% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | AU$298.86M | 27.58 | -15.96% | ― | 364.97% | 74.50% | |
49 Neutral | AU$34.92M | -5.38 | -19.10% | ― | ― | -285.37% | |
43 Neutral | AU$109.49M | -5.66 | -100.58% | ― | ― | -9.57% | |
42 Neutral | AU$56.78M | -5.28 | -62.49% | ― | ― | -13.64% | |
40 Underperform | AU$32.70M | -10.60 | -142.30% | ― | -45.25% | 40.54% |
* Healthcare Sector Average
AU:ILA
Island Pharmaceuticals Ltd
0.37
0.19
105.56%
AU:CYP
Cynata Therapeutics Limited
0.32
0.13
65.13%
AU:PTX
Prescient Therapeutics Limited
0.05
<0.01
8.00%
AU:SPL
Starpharma Holdings Limited
0.71
0.62
655.32%
AU:ADO
AnteoTech Ltd
0.01
<0.01
10.00%
AU:NSB
Neuroscientific Biopharmaceuticals Ltd.
0.11
0.05
110.00%
Island Pharmaceuticals Ltd Corporate Events
Island Pharmaceuticals Issues New Shares on Option Exercise, Affirms Regulatory Compliance
Apr 27, 2026
Island Pharmaceuticals has issued 335,000 fully paid ordinary shares following the exercise of unlisted options at an issue price of $0.21 per share, expanding its share capital without undertaking a separate disclosure document. The company confi...
Island Pharmaceuticals Seeks ASX Quotation for 335,000 New Shares
Apr 27, 2026
Island Pharmaceuticals has applied for quotation on the ASX of 335,000 new ordinary fully paid shares, with an issue date of April 27, 2026. The additional securities, arising from the exercise or conversion of existing instruments, modestly expan...
Island Pharmaceuticals secures FDA alignment and funding to advance Galidesivir biodefence program
Apr 26, 2026
Island Pharmaceuticals reported significant progress in the March quarter in advancing Galidesivir, securing clear alignment from the U.S. Food and Drug Administration on the drug’s Animal Rule development pathway and validation of its Marbu...
Island Pharmaceuticals Issues New Shares on Option Exercise, Affirms Regulatory Compliance
Mar 30, 2026
Island Pharmaceuticals has issued 125,000 fully paid ordinary shares following the exercise of unlisted options at an issue price of $0.21 per share, expanding its share capital without undertaking a new disclosure document. The company stated it ...
Island Pharmaceuticals Seeks Quotation for Additional 125,000 ASX Shares
Mar 30, 2026
Island Pharmaceuticals has applied to the ASX for quotation of an additional 125,000 ordinary fully paid shares, to be issued on March 30, 2026. The modest increase in quoted securities, arising from the exercise or conversion of existing instrume...
Island Pharmaceuticals Issues New Shares on Option Conversion, Affirms Compliance
Mar 22, 2026
Island Pharmaceuticals has issued 690,000 fully paid ordinary shares following the exercise of unlisted options at an issue price of $0.21 per share. The move modestly increases the company’s share capital and reflects the conversion of exis...
Island Pharmaceuticals Seeks ASX Quotation for 690,000 New Shares
Mar 22, 2026
Island Pharmaceuticals Ltd has applied for quotation on the ASX of 690,000 new ordinary fully paid shares, to be traded under its existing ticker ILA. The new securities, issued on March 23, 2026, modestly expand the company’s listed share b...
Island Pharmaceuticals Halts Trading Ahead of Biodefence Deal Announcement
Mar 1, 2026
Island Pharmaceuticals has requested a trading halt in its shares on the ASX, effective from the start of trading on 2 March 2026. The halt will remain in place until either the commencement of normal trading on 4 March 2026 or the earlier release...
Island Pharmaceuticals posts wider half-year loss despite uptick in asset backing
Feb 25, 2026
Island Pharmaceuticals Limited reported a sharp increase in its half-year loss for the period ended 31 December 2025, with the loss after tax widening to $4.81 million from $1.53 million a year earlier. Despite the deeper loss, net tangible assets...
Island Pharmaceuticals Defends Handling of FDA Feedback in ASX Query
Feb 10, 2026
Island Pharmaceuticals has responded to an ASX price query, confirming that recent feedback from the U.S. Food and Drug Administration on the development pathway for its antiviral candidate Galidesivir was materially price-sensitive. The company d...
Island Pharmaceuticals Outlines Strategy on Urgent Viral Threats in Investor Presentation
Feb 5, 2026
Island Pharmaceuticals Limited has released an investor-focused presentation outlining its activities in combating urgent viral disease threats and providing an overview of its business and risk profile. The document emphasises that the material i...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.